PDCD1 and neoplasm: Two anti-TIM-3 mAbs, MGB453 (Novartis) and TSR-022 (TESARO), are under phase I/II clinical trials; the results are not published yet; the efficacy of and tolerance to combination immune therapy using anti-TIM-3 and anti-PD-1 mAbs are unknown, but research on TIM-3 has shown considerable potential in tumor metastasis treatment.